Public Sector Pension Investment Board Has $21.32 Million Stock Holdings in Alkermes plc $ALKS
Public Sector Pension Investment Board raised its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 11.6% during the third quarter, according to its most recent disclosure with the Securities...
WAT tops Q4 estimates as revenues rise 7% Y/Y, with strong Pharma and Europe growth, and upbeat 2026 sales and earnings outlook.
Zacks·1d ago
SNY Stock Falls After Board Suddenly Makes Leadership Change
Sanofi stock slides 4.5% after it decides not to renew CEO Paul Hudson's mandate and names Belen Garijo as successor amid investor skepticism.
Zacks·1d ago
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.
Zacks·1d ago
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss
AGIO beats fourth-quarter estimates for both the top and bottom lines as Pyrukynd sales jump 49% year over year.
Zacks·1d ago
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027.
Zacks·1d ago
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
Zacks·1d ago
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down
Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.
Zacks·1d ago
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates
CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.
Zacks·1d ago
MDGL Strengthens MASH Franchise With New Genetic Approaches
Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidates, expanding MASH pipeline and eyeing FDA filings in 2026.